Does PEMBROLIZUMAB Cause Recurrent cancer? 107 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 107 reports of Recurrent cancer have been filed in association with PEMBROLIZUMAB (KEYTRUDA). This represents 0.1% of all adverse event reports for PEMBROLIZUMAB.
107
Reports of Recurrent cancer with PEMBROLIZUMAB
0.1%
of all PEMBROLIZUMAB reports
6
Deaths
11
Hospitalizations
How Dangerous Is Recurrent cancer From PEMBROLIZUMAB?
Of the 107 reports, 6 (5.6%) resulted in death, 11 (10.3%) required hospitalization, and 1 (0.9%) were considered life-threatening.
Is Recurrent cancer Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for PEMBROLIZUMAB. However, 107 reports have been filed with the FAERS database.
What Other Side Effects Does PEMBROLIZUMAB Cause?
Malignant neoplasm progression (10,111)
Death (4,744)
Diarrhoea (4,251)
Fatigue (3,833)
Off label use (3,416)
Product use in unapproved indication (3,191)
Pyrexia (3,155)
Rash (2,900)
Nausea (2,670)
Decreased appetite (2,486)
What Other Drugs Cause Recurrent cancer?
NIRAPARIB (776)
IMATINIB (237)
CYCLOPHOSPHAMIDE (143)
TRASTUZUMAB (121)
CAPECITABINE (108)
RITUXIMAB (99)
DOXORUBICIN (97)
OCTREOTIDE (95)
METHOTREXATE (81)
OLAPARIB (77)
Which PEMBROLIZUMAB Alternatives Have Lower Recurrent cancer Risk?
PEMBROLIZUMAB vs PEMETREXED
PEMBROLIZUMAB vs PEMIGATINIB
PEMBROLIZUMAB vs PENICILLAMINE
PEMBROLIZUMAB vs PENICILLIN
PEMBROLIZUMAB vs PENICILLIN G